Evidence map›Paper›PMID 38485469›Full record

ArticleJournal of the American Geriatrics Society2024

Attitudes on participation in clinical drug trials: A nationally representative survey of older adults with multimorbidity.

Janice B Schwartz, Ruey-Ying Liu, John Boscardin, Qi Liu, S W Johnny Lau, Sadhna Khatri, Derjung Tarn

Erratum issuedOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Geriatrics Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
13.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Representation of Older Adult Patients in Clinical Trials.Clinical and translational science · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Janice B SchwartzDepartment of Medicine, Division of Geriatrics and Division of Clinical Pharmacology, University of California, San Francisco, California, USA.ORCID 0000-0002-5171-7824
Ruey-Ying LiuDepartment of Sociology, National Chengchi University, Taipei, Taiwan.ORCID 0000-0002-2770-2147
John BoscardinDepartment of Medicine and Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.ORCID 0000-0003-3121-9526
Qi LiuCenter for Drug Evaluation and Research, Office of Translational Sciences and Office of Clinical Pharmacology, U.S. Food and Drug Administration, Silver Springs, Maryland, USA.ORCID 0000-0002-4053-4213
S W Johnny LauCenter for Drug Evaluation and Research, Office of Translational Sciences and Office of Clinical Pharmacology, U.S. Food and Drug Administration, Silver Springs, Maryland, USA.ORCID 0000-0002-1369-457X
Sadhna KhatriCenter for Biologics Evaluation and Research, Office of Compliance Biologics Quality, U.S. Food and Drug Administration, Silver Springs, Maryland, USA.ORCID 0009-0006-3801-1858
Derjung TarnDepartment of Family Medicine, University of California, Los Angeles, California, USA.ORCID 0000-0001-7426-6387
United States Food and Drug Administration · USUniversity of California, San Francisco · USCenter for Biologics Evaluation and Research · USNational Chengchi University · TWUniversity of California, Los Angeles · US

Funding

UCSF-Stanford Center of Excellence in Regulatory Science and InnovationU01FD005978 · FDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALTMAN, RUSS BIAGIO, GIACOMINI, KATHLEEN M · 2016 to 2025
$34.5M
FDA HHS U01 FD005978U.S. Food and Drug Administration U01FD005978
6 · The paper itself

Abstract

backgroundOlder adults with multimorbidity are under-represented in clinical drug trials. Their inclusion will not increase unless they are willing and able to participate. Data on motivators and barriers to participation in trials of new medications of older adults with multimorbidity are needed.

methodsCross-sectional internet and telephone survey of a nationally representative sample of adults ≥65 years with ≥3 chronic conditions (NORC University of Chicago Amerispeak Panel) conducted from March-April, 2023 to determine motivators and barriers to drug trial participation, described graphically and using statistics.

resultsSurveyed 1318 (1142 Internet, 176 phone) with mean age 72.3 ± 6.3 (SD), 52% women; race: 83% White, 10% Black or African American, 5% Hispanic or Latino, 1.1% Asian; 4.4 ± 1.9 chronic conditions (of 16 queried), taking 7.5 ± 3.3 medications. Barriers included fear of side effects (48%), taking too many medications (44%), placebo (44%), mobility (33%), bathroom needs (25%), hearing (19%), eyesight (15%), video visits (33%; higher in women, Black or African-American respondents, and those ≥80 years). Sixty-five percent would join all in-person trials, 49% would join all-video trials. Travel >1 h was difficult for 66%, most difficult for women. Trust was a concern in 25% of Black respondents. Caregiving responsibilities or lack of time were not obstacles. Participants were most likely to consider a drug trial for a problem they have (63%) versus prevention (44%) and if invited by a physician (80%) or University healthcare system (58%). Getting better care was ranked very important (79%) followed by helping others (57%).

conclusionsMajor concerns of older patients with multimorbidity about participation in drug trials are potential side effects, taking too many medicines, and video visits. Physicians have the greatest influence on decisions and in-person visits are preferred. Proposed changes in trial design to increase enrollment of under-represented older adults may not align with patient-reported preferences.

Indexed as

Clinical Trials as TopicMultimorbidityAgedAged, 80 and overChronic DiseaseCross-Sectional StudiesFemaleHumansMaleMotivationPatient ParticipationSurveys and QuestionnairesUnited Statesbarriersclinical trialsmotivatorsmultimorbidityolder adults

Identifiers

PMID38485469
PMCPMC11187642
OpenAlexW4392860689

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.